DUBLIN – Genable Technologies Ltd. is dipping into Philadelphia’s deep pool of gene therapy expertise by entering a collaboration agreement with Spark Therapeutics LLC, under which the latter firm will provide manufacturing services and clinical development assistance on its lead program, GT038, currently in preclinical development for rhodopsin-linked autosomal dominant retinitis pigmentosa (RP).